经导管动脉化疗栓塞术联合微波消融治疗肝癌的临床研究

Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of liver cancer

目的探讨经导管动脉化疗栓塞(TACE)术联合微波消融治疗肝癌的临床效果。方法选取2014年6月～2015年10月我院收治的36例肝癌患者作为研究对象,按照随机数字表法分为对照组和研究组,每组各18例,对照组患者进行TACE术治疗,研究组患者进行TACE术联合微波消融治疗。比较两组患者的近期和远期疗效。结果研究组治疗2个月后的肿瘤完全坏死率(83.33%)明显高于对照组(16.67%),差异有统计学意义(P<0.05);研究组治疗2个月后的部分坏死率(16.67%)明显低于对照组(83.33%),差异有统计学意义(P<0.05);研究组患者的1年生存率(83.33%)明显高于对照组(44.44%),差异有统计学意义(P<0.05);研究组患者的2年生存率(44.44%)明显高于对照组(5.56%),差异有统计学意义(P<0.05)。结论 TACE术联合微波消融治疗肝癌,肿瘤完全坏死率高,有良好的近期和远期疗效,值得临床推广应用。

Objective To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with microwave ablation in the treatment of liver cancer. Methods Thirty-six patients with liver cancer admitted to our hospital from June 2014 to October 2015 were selected as the study subjects,they were divided into control group and study group according to random number table method,with 18 cases in each group,the control group was treated with TACE and the study group was treated with TACE combined with microwave ablation. The short-term and long-term effects of the two groups were compared. Results The total necrosis rate of tumors (83.33%) in the study group was significantly higher than that in the control group (16.67%) after 2 months of treatment,the difference was significant (P<0.05). The partial necrosis rate (16.67%) in the study group was significantly lower than that in the control group (83.33%) after 2 months of treatment ,the difference was significant (P<0.05). The one-year survival rate of the study group (83.33%) was significantly higher than that of the control group (44.44%),the difference was significant (P<0.05). The two-year survival rate of the study group (44.44%) was significantly higher than that of the control group (5.56%),the difference was significant (P<0.05). Conclusion TACE combined with microwave ablation in the treatment of liver cancer has a high rate of complete necrosis and good short-term and long-term efficacy,which is worthy of clinical application.